Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials
← catalyst calendarNCT05492578 · readout in 887 d
Sponsored by Sanofi (industry) · SNY — their whole pipeline →.
Phase
Phase 2/3
Status
Enrolling by invitation
Study type
Interventional
Design
Non randomized · None · Treatment
Enrollment
1,663estimated
Sites
390
Countries
Argentina, Australia, Brazil +26
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2022-08-22 | actual | When the study began enrolling |
| Primary completion | 2029-01-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2029-01-22 | estimated | The whole study's end, after follow-up |
| First posted | 2022-08-08 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-07-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dermatitis Atopic
Interventions
- Drug: Amlitelimab — also filed as SAR445229
- Drug: Topical corticosteroids
- Drug: Topical calcineurin inhibitors
- Drug: Oral corticosteroids
Primary outcome
what the primary-completion date above is the date OFPercentage of participants who experienced treatment-emergent adverse event (TEAE)
measured Baseline to Week 332
Permalink · SNY's whole pipeline · Catalyst calendar · Every registered study · What changed